Curaleaf Holdings Inc (CURA.TO) Buy, Sell or…

Home

Daily Stock Opinions and Ratings

Curaleaf Holdings Inc (CURA.TO)

13.45

+0.46 (3.54%)

as of Aug 28, 2026, 8:00:00 pm Market Open.

119 watching

Investor Insights

Aug 31, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Curaleaf Holdings Inc (CURA) has garnered attention due to the potential rescheduling of cannabis, which could significantly reduce tax burdens for companies in the sector. Although excitement surged last year, leading to volatile spikes in stock prices, experts emphasize the unpredictability surrounding legislative changes in cannabis laws. Competitors like Trulieve (TRUL) are mentioned as being in a similar position, showcasing the sector's dual nature of potential growth alongside inherent risks tied to political developments. Despite challenges related to tax restrictions on business expenses, the overall sentiment is cautiously optimistic, as the industry's financials have improved, presenting opportunities for undervalued stocks in the cannabis market. However, investors are advised to maintain small positions until cash flow becomes more stable.

Consensus

Cautious

Valuation

Undervalued

Similar

Trulieve,TRUL

TOP PICK

Operates entirely in the US. Largest marijuana producer in the world by sales. Vertically integrated. Growing quickly organically and by acquisition. Regulatory tailwind. Democrats taking Senate increase likelihood of legislative reform. Great company, lots of growth runway. No dividend. (Analysts’ price target is $19.98)

Wealthica Track your Stocks in your Watch List

BUY

It's the largest US MSO (multi-state operator) in several U.S. states. They've built up a small private company over two years, then went public. MSOs are capturing more attention and capital flows.

TOP PICK

Operates entirely in US, with 10x the market. Canadian red tape has made it difficult for regulated companies to take market share from black market. Whereas US market is undersupplied. Vertical integration and geographic diversity are part of its strategy. Good management. No dividend. (Analysts’ price target is $17.47)

HOLD

He finds it fascinating that cannabis is still illegal in the US, but is deemed essential during the pandemic. He thinks this will lead to relaxed regulations in the future. The company generates increasing revenue and positive cash flow -- only a handful of US cannabis companies do. He thinks it will be a dominant player in years to come in the space.

BUY

CURELF-N vs. CL-X. He really made a focus on the US for cannabis. He thinks the US MSOs have a tremendous amount of room to go. CURELF-N is one of the leaders. CL-X just did a deal in California, which is one of the biggest markets out there. He likes both of them. They are both leaders.

Showing 31 to 35 of 35 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Jim Lebenthal

Cerity Partners

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Brianne Gardner

Raymond James

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Curaleaf Holdings Inc (CURA.TO)